MedTrace Logo

Copeptin Kinetics in Critically Ill Patients With Posterior Reversible Encephalopathy Syndrome

NCT04950270 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 24

Last updated 2024-07-22

No results posted yet for this study

Summary

XPRESSE is a multicenter observational prospective biomarker study in which critically ill patients with MRI-based PRES diagnosis will have copeptin kinetics from a daily blood sample for 6 days and a 3-month follow-up. This study aims to investigate the relationship between copeptin and PRES in order to establish the optimal therapeutic time window for vaptan treatment against PRES.

Data collection using an electronic case report form will include demographic data, medical history and data related to PRES: onset modalities and date of symptoms control, radiological features of PRES, biological investigations, results of etiological investigations and therapeutic management (e.g., anticonvulsants, antihypertensive drugs, supportive treatments). Outcomes will include modified Rankin scale score and Glasgow Outcome Scale score at ICU discharge, 3-month modified Rankin Scale score and 3-month mortality.

Conditions

  • Posterior Reversible Encephalopathy Syndrome

Interventions

BIOLOGICAL

Blood copeptin monitoring

Blood copeptin monitoring during the first 6 days of ICU stay with PRES

OTHER

phone interview

Structured phone interview at 3 months to collect vital status and modified Rankin Scale score

Sponsors & Collaborators

  • University Hospital, Tours

    lead OTHER

Principal Investigators

  • Bérenger LARGEAU, PharmD · University Hospital, Tours

  • Charlotte SALMON GANDONNIERE, MD, PhD · University Hospital, Tours

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-06-18
Primary Completion
2024-02-26
Completion
2024-02-26

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04950270 on ClinicalTrials.gov